Addiction

A discussion with a director from the American Public Health Association on what drives the increasing burden of mental illness in the US.

How physicians in a shrinking field have taken on a greater burden of leadership roles in patient care.

How does psychiatry access differ among patients, and how should it become individualized?

A recent study of more than 200,000 injured workers identified risk factors of opioid use of a previously opioid-free population.

A clinical trial of 147 individuals found that a 15-week treatment program using cognitive behavioral therapy may be a promising treatment for internet and video game addictions.

For chronic pain sufferers using opioids, policy changes have made it difficult to find new primary care providers — which investigators warn could have unintended consequences.

A recent study found that 65% of adult users reported using cannabis for pain relief and 88% of those taking opioid analgesics reported reducing or discontinuing use of medications.

The NMDA receptor, in combination with rehabilitation, may serve as a powerful agent for reducing relapse rates.

Contrary to earlier research, investigators found that medical cannabis laws do not reduce deaths caused by opioid overdoses.

A new report from VHA shows synthetic opioids have accounted for a significant count of veteran deaths since 2010.

Jonathan Avery, MD, addiction psychiatrist and associate professor of psychiatry, sat down with MD Magazine at APA 2019 to discuss his takeaways and caring for patients with co-occurring mental illness and substance use disorder.

A recent study found that recreational cannabis legalization can lead to increase in car accidents and injuries, but decreases in chronic pain admissions.

A recent study from the Mayo Clinic found that tramadol carries a risk of long-term use similar to that of oxycodone and hydrocodone.

A randomized trial compared cash incentives, peer support, and usual care for increasing rate of HCV treatment among HCV/HIV infected people who use drugs.

A recent study found that black patients were far less likely to be prescribed buprenorphine than white patients.

The lot is being voluntarily recalled due to a detected microbial growth during a routine manufacturing simulation—indicating a potential introduction of microorganisms into the therapy.

Unlike injectable versions, naloxone nasal spray may be administered outside a health care setting by anyone, regardless of medical training.

For expectant parents who smoke, quitting before pregnancy or as early as possible during pregnancy was associated with a reduced risk of preterm birth.

A new Northwell Health study showed that setting a chronic standard-of-care plan and correcting outliers could influence opioid prescription rates.

How a biopsychosocial approach to assessing pain better aligns with the realities of treating pain pathways—and how that can limit opioid depedence.

An extended-release, subcutaneous injection form of buprenorphine (Sublocade) demonstrated long-term efficacy and safety results.

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

A short account of patients I’ve known and not loved over the years.

Pain management protocols for women undergoing C-sections, that include a non-opioid option such as EXPAREL, can help improve pain management and reduce the need for opioids.

Investigators found that the prevalence of asthma in patients with opioid dependence was more than double the national prevalence.